View Older Stories View More Recent Stories

Sep 16, 2019 07:30AM Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Sep 13, 2019 07:32AM Alnylam Pharma (ALNY) Presents New Evidence Demonstrating Significant Association of V122I with Clinical Diagnosis of Polyneuropathy
Sep 13, 2019 07:30AM Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy
Sep 11, 2019 08:30AM 1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day
Sep 10, 2019 06:17AM Alnylam Pharma (ALNY) presents New Clinical Results for Givosiran at ICPP
Sep 10, 2019 05:30AM Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
Sep 6, 2019 07:30AM Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series
Sep 3, 2019 07:33AM Alnylam Pharma (ALNY) Presents New Clinical Research Findings at Second European Meeting of ATTR Amyloidosis for Doctors and Patients
Sep 3, 2019 07:30AM Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients
Sep 3, 2019 05:55AM Alnylam Pharma (ALNY) Presents Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran
Sep 2, 2019 03:05AM Alnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran
Aug 30, 2019 08:00AM Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference
Aug 14, 2019 08:00AM Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
Aug 13, 2019 07:31AM Ironwood (IRWD), Alnylam Pharma (ALNY) Enter U.S. GI Disease Education and Promotional Agreement for Alnylam's Givosiran in AHP
Aug 13, 2019 07:30AM Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
Aug 13, 2019 07:30AM Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
Aug 6, 2019 07:30AM Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity
Aug 5, 2019 05:10PM Alnylam Pharma (ALNY) Announces FDA Granted Priority Review of Givosiran NDA for Treatment of Acute Hepatic Porphyria
Aug 5, 2019 04:00PM Alnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria
Jul 23, 2019 04:00PM Alnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results
Jul 16, 2019 07:00AM Alnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis
Jul 11, 2019 08:33AM Alnylam Pharma (ALNY) Announces Transition of CFO
Jul 11, 2019 08:30AM Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer
Jun 24, 2019 07:13AM Alnylam Pharma (ALNY) Presents New ONPATTRO Results at PNS
Jun 24, 2019 07:00AM Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting
Jun 21, 2019 07:01AM Alnylam Pharma (ALNY) Announces Progress with RNAi Therapeutics Platform
Jun 21, 2019 07:00AM Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
Jun 18, 2019 08:01AM Alnylam Pharma (ALNY) Announces Approval in Japan of ONPATTRO for Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Jun 18, 2019 08:00AM Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Jun 17, 2019 07:02AM Alnylam Pharma (ALNY) Reports Complete Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with PH1
Jun 17, 2019 07:00AM Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
Jun 13, 2019 08:00AM Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN)
Jun 5, 2019 07:03AM Alnylam Pharma (ALNY) Completes Rolling Submission of NDA to FDA for Givosiran for Treatment of Acute Hepatic Porphyria
Jun 5, 2019 07:00AM Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
May 31, 2019 07:02AM Alnylam Pharma (ALNY) Reports First Patient Dosing in Phase 1 Study of ALN-AGT
May 31, 2019 07:00AM Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
May 30, 2019 04:00PM Alnylam to Webcast Presentations at Upcoming June Investor Conferences
May 29, 2019 08:00AM Alnylam Announces New Leadership Appointments
May 9, 2019 07:00AM Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
May 1, 2019 08:00AM Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
Apr 30, 2019 04:00PM Alnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran)
Apr 23, 2019 04:00PM Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results
Apr 15, 2019 07:03AM Alnylam Pharma (ALNY) Initiates ILLUMINATE-B Phase 3 Pediatric Study
Apr 15, 2019 07:00AM Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
Apr 15, 2019 06:53AM Alnylam Pharma (ALNY) Announces Positive ENVISION Phase 3 Study of Givosiran
Apr 12, 2019 06:01PM Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
Apr 8, 2019 07:02AM Alnylam (ALNY), Regeneron (REGN) Announce Pact on RNAi Therapeutics Focused on Ocular and CNS Diseases; Regeneron to Make Payment of $400M Upfront and Purchase Stock at $90/Share
Apr 8, 2019 07:00AM Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Apr 8, 2019 07:00AM Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Apr 8, 2019 06:32AM Alnylam Pharma (ALNY), Sanofi (SNY) Conclude Research and Option Phase of RNAi Therapeutics Collaboration
View More Recent Stories View Older Stories